Exactly One Oxygen Bonded Directly To The Cyclopentanohydrophenanthrene Ring System (e.g., 3-keto-etiocholanic Acids, Etc.) Patents (Class 552/611)
  • Patent number: 9855281
    Abstract: A composition for enhancing libido of a pharmaceutically effective amount of a libido-enhancing therapeutic of (5S,10R,13S,17S)-13-methyl-3-oxohexadecahydro-1H-cyclopenta[a]phenanthren-17yl acetate (Formula I), (3S,5S,10R,13S,17S)-3-hydroxy-13-methylhexadecahydro-1H-cyclopenta[a]phenanthren-17yl acetate (Formula II), (5S,10S,13S,17S)-17-hydroxy-13-methyltetradecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one (Formula III), isomers thereof, analogs thereof, or combinations thereof, and a pharmaceutically acceptable carrier. A method of enhancing libido, by administering the composition to an individual in need of an enhanced libido, and enhancing libido in the individual or animal which is male or female. A method of enhancing libido, by administering the composition of the present invention to an individual at an age when libido and sexual desire have naturally decreased, and enhancing libido in the individual.
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: January 2, 2018
    Assignee: Scott Freeman Consultant, LLC
    Inventor: Scott Freeman
  • Publication number: 20140235600
    Abstract: The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: December 18, 2013
    Publication date: August 21, 2014
    Applicant: Washington University
    Inventors: Douglas Covey, Albert Jean Robichaud
  • Patent number: 8586770
    Abstract: The invention relates to methods to manipulate stem cells in vivo and in vitro to treat, e.g., a condition where cell or tissue repair is needed.
    Type: Grant
    Filed: February 18, 2011
    Date of Patent: November 19, 2013
    Assignee: Harbor Therapeutics, Inc.
    Inventor: James M. Frincke
  • Patent number: 8207150
    Abstract: The 17?-cyano-19-nor-androst-4-ene derivatives of the present invention possess gestagenic activity.
    Type: Grant
    Filed: June 11, 2008
    Date of Patent: June 26, 2012
    Assignee: Bayer Pharma AG
    Inventors: Joachim Kuhnke, Jan Huebner, Rolf Bohlmann, Thomas Frenzel, Ulrich Klar, Frederik Menges, Sven Ring, Steffen Borden, Hans-Peter Muhn, Katja Prelle
  • Publication number: 20110014641
    Abstract: The present invention relates to compounds useful for measuring aromatase activity. The invention further provides methods for measuring aromatase activity and for screening test agents which modulate aromatase activity. A kit is also provided for use in such screening methods.
    Type: Application
    Filed: September 28, 2010
    Publication date: January 20, 2011
    Applicant: GE HEALTHCARE UK LIMITED
    Inventors: JOHN GERARD WHATELEY, RAHMAN AZIZ ISMAIL, PETER GORDON LAUGHTON
  • Publication number: 20100292184
    Abstract: The 17?-cyano-19-androst-4-ene derivatives of the present invention possess gestagenic activity.
    Type: Application
    Filed: June 12, 2008
    Publication date: November 18, 2010
    Applicant: BAYER SCHERING PHARMA AG
    Inventors: Joachim Kuhnke, Jan Huebner, Rolf Bohlmann, Thomas Frenzel, Ulrich Klar, Frederik Menges, Sven Ring, Steffen Borden, Hans Peter Muhn, Katja Prelle
  • Publication number: 20100160657
    Abstract: The present invention relates to new synthetic receptors. More particularly, the present invention relates to methods for synthesizing preferred membrane-binding elements, preferably cholesterylamine derivatives, including 3?-amino-5-cholestene (3?-cholesterylamine) and related 3?-halides through i-steroid and retro-i-steroid rearrangements. The invention further relates to use of the synthetic receptors for delivering a protein, peptide, drug, prodrug, lipid, nucleic acid, carbohydrate or small molecule into a target cell via receptor-mediated endocytosis. According to the invention, novel synthetic mimics of cell surface receptors have been designed and methods for use of the same are disclosed.
    Type: Application
    Filed: December 11, 2009
    Publication date: June 24, 2010
    Applicant: THE PENN STATE RESEARCH FOUNDATION
    Inventors: BLAKE R. PETERSON, QI SUN
  • Patent number: 7691836
    Abstract: The subject invention provides a compound according to Formula I, wherein each of the substituents is given the definition as set forth in the specification and claims, or a pharmaceutically acceptable salt and/or hydrate form and/or prodrug thereof.
    Type: Grant
    Filed: March 18, 2005
    Date of Patent: April 6, 2010
    Assignee: N.V. Organon
    Inventors: Johannes Antonius Maria Hamersma, Johannes Bernardus Maria Rewinkel
  • Publication number: 20100056488
    Abstract: The invention features corticosteroids conjugated to either a charged group or a bulky group in a manner that resists in vivo cleavage, the resulting conjugate is a peripherally acting steroid with reduced activity in the central nervous system. The invention provides a method for treating a patient having an inflammatory disease by administering to the patient a corticosteroid conjugate.
    Type: Application
    Filed: November 4, 2009
    Publication date: March 4, 2010
    Applicant: The McLean Hospital Corporation
    Inventors: Martin H. Teicher, Susan L. Andersen-Navalta
  • Publication number: 20100041906
    Abstract: The present invention concerns a method for the controlled precipitation of organic compounds giving crystals with a very small average size and a very narrow size distribution.
    Type: Application
    Filed: January 26, 2007
    Publication date: February 18, 2010
    Inventors: Huibert Albertus Van Boxtel, Servatius Hubertus Johannes Wilhelmus Leenen, Matheus Lambertus Spapens
  • Publication number: 20090187032
    Abstract: The present invention relates to a new industrial process for the synthesis of solvate-free 17?-acetoxy-11?-[4-(N,N-dimethyl-amino)-phenyl]-19-norpregna-4,9-diene-3,20-dione [CDB-2914] of formula (I) which is a strong antiprogestogene and antiglucocorticoid agent. The invention also relates to compounds of formula (VII) and (VIII) used as intermediates in the process.
    Type: Application
    Filed: May 18, 2007
    Publication date: July 23, 2009
    Applicant: RICHTER GEDEON NYRT.
    Inventors: Lajosne Dancsi, Gyorgy Visky, Zoltan Tuba, Janos Csorgei, Csaba Molnar, Endrene Magyari
  • Publication number: 20090131388
    Abstract: To inhibit production of adipocytokines, in particular, adipocytokines that elicit insulin resistance and to prevent onset of pathosis caused by the insulin resistance or ameliorate the pathosis, the present invention provides an agent or a food or drink which contains a compound having a lophenol skeleton, or an organic solvent extract or a hot water extract of a Liliaceae plant or, a fraction thereof containing the compound as an active ingredient.
    Type: Application
    Filed: September 22, 2006
    Publication date: May 21, 2009
    Applicant: MORINAGA MILK INDUSTRY CO., LTD.
    Inventors: Miyuki Tanaka, Eriko Misawa
  • Publication number: 20090042844
    Abstract: Compounds having the structure, their salts or N-oxide derivatives: are used to treat or reduce le likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia and male baldness. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Combinations with other active pharmaceutical agents are also disclosed.
    Type: Application
    Filed: April 9, 2008
    Publication date: February 12, 2009
    Inventors: Fernand LABRIE, Sylvain GAUTHIER, Julie CLOUTIER, Josee MAILHOT, Steeves POTVIN, Sylvain DION, Jean-Yves SANCEAU
  • Patent number: 7402577
    Abstract: Compounds of structural formula as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the function of the androgen receptor in a patient, and in particular the method wherein the function of the androgen receptor is blocked in the prostate of a male patient or in the uterus of a female patient and activated in bone and/or muscle tissue.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: July 22, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Jiabing Wang, Mark E. Duggan, David B. Whitman
  • Patent number: 7371741
    Abstract: Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula: wherein the variables are defined in the specification.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: May 13, 2008
    Assignee: EntreMed, Inc.
    Inventors: Gregory E. Agoston, Theresa M. LaVallee, Victor S. Pribluda, Jamshed H. Shah, Anthony M. Treston
  • Patent number: 7199115
    Abstract: New 17?-fluorosteroid compounds of formula (I) are disclosed: wherein R1 denotes H or methyl; R2 and R3 each denote H, Cl or methyl; and either a double bond or a single bond is present between C-6 and C-7 and also C-9 and C-10 of the steroid ring system respectively. These compounds have an activity profile with hybrid character so that they act as inhibitors for 5?-reductase and as high potency gestagens. Pharmaceutical compositions containing them are disclosed. They are suitable for treatment of conditions, which are caused by high levels of androgen in organs and tissues. These new compounds can be used in combination with other hormonal substances, such as estrogens, testosterone and other androgens, as contraceptives and for other applications.
    Type: Grant
    Filed: April 13, 2005
    Date of Patent: April 3, 2007
    Assignee: Schering AG
    Inventors: Ulrich Bothe, Peter Droescher, Walter Elger, Gudrun Reddersen, Bernd Menzenbach, Hans-Udo Schweikert, Alexander Hillisch, Birgitt Schneider
  • Patent number: 6953785
    Abstract: Provided is steroid sulfatase inhibitors comprising, as the active ingredient, an estra-1,3,5(10)-triene derivative which is represented by formula (I): {wherein R1 and R2 are the same or different and represent a hydrogen atom, a lower alkyl group or, etc.; R3 represents a hydrogen atom etc.; R4 represents a hydrogen atom etc.; R5 represents a hydrogen atom etc.; R6 represents a cyano group, an amino group, COR53 (wherein R53 represents a substituted lower alkyl group etc.), a substituted or unsubstituted aryl group, a substituted or unsubstituted heterocyclic group, etc}, or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 24, 2001
    Date of Patent: October 11, 2005
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Yoji Ino, Nobuyoshi Amishiro, Mayumi Miyata, Tsutomu Agatsuma, Kozue Muramatsu, Takeshi Takahashi, Shiro Akinaga, Chikara Murakata
  • Patent number: 6638923
    Abstract: Estra-1,3,5(10),16-tetraene derivatives represented by the following formula (I): (wherein R1 is as defined by the present specification.
    Type: Grant
    Filed: May 18, 2001
    Date of Patent: October 28, 2003
    Assignees: Kyowa Hakko Kogyo Co., Ltd., Duquesne University of the Holy Ghost
    Inventors: Yoji Ino, Nobuyoshi Amishiro, Taisuke Nakata, Hiroyuki Ishida, Shiro Akinaga, Chikara Murakata, Pui-Kai Li
  • Patent number: 6610866
    Abstract: A method is described for stereoselectively reducing an unsaturated alkyl ketone substituent attached to a fused ring base. In this method, the unsaturated alkyl ketone reacts with a chiral oxazaborolidine reagent. This reaction stereoselectively reduces the unsaturated alkyl ketone to an unsaturated alkyl alcohol. The unsaturated alkyl alcohol can be further reduced, if desired, to produce a saturated alkyl alcohol. The fused ring base can be, for example, a steroid ring base or a base of a vitamin D analog. The process in accordance with the invention can be used with an alkeneone substituent (e.g., a 22-ene-24-one substituent) or an alkyneone substituent (e.g., a 22-yne-24-one substituent) on a steroid ring base to make squalamine or other useful aminosterol compounds and intermediates for making aminosterol compounds.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: August 26, 2003
    Assignee: Magainin Pharmaceuticals, Inc.
    Inventors: William A. Kinney, Steven Jones, Xuehai Zhang, Meena N. Rao, Michel Bulliard, Harold Meckler, Nancy Lee
  • Patent number: 6596885
    Abstract: Novel compounds having a formula selected from the group consisting of wherein the substituents are defined as in the specification which are intermediates for the production of vinyl compounds having a remarkable anti-estrogenic and anti-proliferative activity.
    Type: Grant
    Filed: June 26, 2001
    Date of Patent: July 22, 2003
    Assignee: Aventis Pharma S.A.
    Inventors: Andre Claussner, Francois Nique, Jean-Georges Teutsch, Patrick Van de Velde
  • Publication number: 20020183532
    Abstract: A compound for supplementing the concentration of a parent androgen in a subject in vivo, wherein the parent androgen has a skeletal structure including a 17 position and the parent androgen further has a 17&bgr;-hydroxy group comprising a 17&bgr;-hydroxy hydrogen appended to the 17 position. The compound comprises a substrate having the skeletal structure of the parent androgen including a 17 position corresponding to the 17 position of the parent androgen, and a promoiety comprising an alkoxymethyl ether appended to the 17 position of the substrate as a substitute for the 17&bgr;-hydroxy hydrogen. Related compounds and methods also are disclosed.
    Type: Application
    Filed: June 1, 2001
    Publication date: December 5, 2002
    Inventor: William J. Roberts
  • Patent number: 6437157
    Abstract: A compound selected from the group consisting of a compound of the formula wherein R1 and R2 are individually selected from the group consisting of alkyl of 1 to 12 carbon atoms and aralkyl of 7 to 15 carbon atoms or taken together form a saturated heterocycle of 5 to 6 ring members optionally having a second ring heteroatom selected from the group consisting of sulfur, oxygen and nitrogen, R3 is an &agr;-alkyl of 1 to 8 carbon atoms, n is an integer from 2 to 15, R4 is alkyl of 1 to 12 carbon atoms, R5 is selected from the group consisting of hydrogen, alkyl of 1 to 12 carbon atoms and acyl of an organic carboxylic acid of up to 12 carbon atoms and the wavy lines indicate that the 17- and 20-asymmetrical centers are independent of the absolute R and S configurations and their non-toxic, pharmaceutically acceptable acid addition salts useful for controlling fertility in male warm-blooded animals.
    Type: Grant
    Filed: March 13, 1995
    Date of Patent: August 20, 2002
    Assignee: Hoechst Marion Roussel
    Inventors: Armelle Bonfils, Daniel Philibert
  • Publication number: 20020103391
    Abstract: The invention relates to novel, androstane steroids which are the ligand semiochemicals which bind to neuroepithelial receptors.
    Type: Application
    Filed: March 9, 2001
    Publication date: August 1, 2002
    Inventors: David L. Berliner, Nathan W. Adams, Clive L. Jennings-White
  • Patent number: 6410760
    Abstract: The process of the present invention transforms a steroidal ketone of formula (III) to androst-4-en-17&bgr;-carboxylic acid (IV) by reaction with K2SO5.KHSO4.K2SO4.
    Type: Grant
    Filed: October 2, 2000
    Date of Patent: June 25, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Kevin C. Grega, Scott W. Ashford
  • Patent number: 6399595
    Abstract: Novel sulfatase inhibitor compounds useful in the treatment of estrogen dependent illnesses are disclosed. These compounds generally comprise a steroid nucleus substituted at the C17 position. Methods for synthesizing these compounds and using them in the therapeutic and/or prophylactic treatment of a patient are also disclosed.
    Type: Grant
    Filed: August 3, 2001
    Date of Patent: June 4, 2002
    Assignees: Duquesne University of the Holy Ghost, Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Pui-Kai Li, Chikara Murakata, Shiro Akinaga
  • Publication number: 20020058651
    Abstract: Estra-1,3,5(10),16-tetraene derivatives represented by the following formula (I): 1
    Type: Application
    Filed: May 18, 2001
    Publication date: May 16, 2002
    Inventors: Yoji Ino, Nobuyoshi Amishiro, Taisuke Nakata, Hiroyuki Ishida, Shiro Akinaga, Chikara Murakata, Pui-Kai Li
  • Patent number: 6376687
    Abstract: Novel sulfatase inhibitor compounds useful in the treatment of estrogen dependent illnesses are disclosed. These compounds generally comprise a steroid nucleus substituted at the C17 position. Methods for synthesizing these compounds and using them in the therapeutic and/or prophylactic treatment of a patient are also disclosed.
    Type: Grant
    Filed: January 24, 2000
    Date of Patent: April 23, 2002
    Assignees: Duquesne University of the Holy Ghost, Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Pui-Kai Li, Chikara Murakata, Shiro Akinaga
  • Patent number: 6288050
    Abstract: Sulfatase inhibitor compounds useful in the treatment of estrogen dependent illnesses are disclosed. These compounds generally comprise a steroid nucleus substituted at the C17 position. Methods for synthesizing these compounds and using them in the therapeutic and/or prophylactic treatment of a patient are also disclosed.
    Type: Grant
    Filed: January 25, 1999
    Date of Patent: September 11, 2001
    Assignees: Duquesne University of the Holy Ghost, Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Pui-Kai Li, Chikara Murakata, Shiro Akinaga
  • Patent number: 6262043
    Abstract: Estra-1,3,5(10),16-tetraene derivatives represented by the following formula (I): (wherein R1 represents hydroxy, alkoxy, or NR2R3 (wherein R2 and R3 are the same or different, and each represents hydrogen, straight-chain lower alkyl having 1 to 3 carbon atoms, or branched-chain lower alkyl having 3 to 8 carbon atoms)), or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 13, 2000
    Date of Patent: July 17, 2001
    Assignees: Kyowa Hakko Kogyo Co., Ltd., Duquesne University of the Holy Ghost
    Inventors: Yoji Ino, Nobuyoshi Amishiro, Taisuke Nakata, Hiroyuki Ishida, Shiro Akinaga, Chikara Murakata, Pui-Kai Li
  • Patent number: 6251887
    Abstract: The invention relates to 17&bgr;-aryl(arylmethyl)oxy(thio)alkyl-androstane derivatives having general formula (I), wherein R1 is (H,OR), (H,OSO3H) or NOR; with R being H, (C1-6)alkyl or (C1-6)acyl; each of R2 and R3 is independently hydrogen or (C1-6)alyl; n is 0, 1, or 2; X is O, S, S(O) or S(O)2; m is 0 or 1; each of R4, R5 and R6 is independently hydrogen, hydroxy, (C1-4)alkoxy, halogen, NR7R8 or (C1-4)alkyl, optionally substituted by hydroxy, alkoxy, halogen or oxo; each of R7 and R8 is independently hydrogen or (C1-4)alkyl, and wherein the dotted lines indicate a &Dgr;7 or a &Dgr;8 double bond, or a pair of conjugated double bonds selected from &Dgr;7,14, &Dgr;8,14 and &Dgr;6,8(14); or a pharmaceutically acceptable salt thereof. The compounds of the invention have meiosis regulating activity and can be used for the control of fertility.
    Type: Grant
    Filed: June 16, 2000
    Date of Patent: June 26, 2001
    Assignee: Akzo Nobel N.V.
    Inventors: Christian Heijmans, Jaap van der Louw
  • Patent number: 6117994
    Abstract: A new process for the preparation of 16.beta.-methyl-steroids of the formula ##STR1## and novel intermediates.
    Type: Grant
    Filed: April 22, 1998
    Date of Patent: September 12, 2000
    Assignee: Hoechst Marion Roussel
    Inventors: Catherine Geurts, Michel Vivat
  • Patent number: 6080735
    Abstract: This invention is relating to new estra-1,3,5(10)-trien-sulfamates carrying at the 3-position an R--SO.sub.2 --O--group, with R being an R.sup.1 R.sup.2 N--group in which R.sup.1 and R.sup.2, independently of each other, represent a hydrogen atom, an alkyl residue with 1-5 C atoms or, together with the N atom, a polymethylene-imino residue with 4-6 C atoms or a morpholino residue.The compounds, according to this invention, are suitable for hormonal contraception and climacteric hormone replacement therapy (HRT) as well as for treatment of gynecological and andrological diseases. Hence, only low hepatic estrogenicity is exhibited by the compounds according to this invention.Also described are processes for preparation of the compounds according to this invention and for preparation of pharmaceutical compositions.
    Type: Grant
    Filed: February 2, 1998
    Date of Patent: June 27, 2000
    Assignee: Jenapharm GmbH & Co. KG
    Inventors: Sigfrid Schwarz, Walter Elger, Hans-Joachim Siemann, deceased, by Margit Lucas, heir, by Frank Siemann, heir, Gudrun Reddersen, Birgitt Schneider
  • Patent number: 5969168
    Abstract: The invention relates to novel, androstane steroids which are the ligand semiochemicals which bind to neuroepithelial receptors. The steroids are useful as ligands to neuroepithelial receptors in the human vomeronasal gland to stimulate autonomic and hypothalamic activity.
    Type: Grant
    Filed: September 29, 1994
    Date of Patent: October 19, 1999
    Assignee: Pherin Corporation
    Inventors: David L. Berliner, Nathan W. Adams, Clive L. Jennings-White
  • Patent number: 5925774
    Abstract: The invention relates to estrene steroids, which bind to neuroepithelial receptors. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.
    Type: Grant
    Filed: June 1, 1995
    Date of Patent: July 20, 1999
    Assignee: Pherin Corporation
    Inventors: David L. Berliner, Nathan W. Adams, Clive L. Jennings-White
  • Patent number: 5880115
    Abstract: Sulfatase inhibitor compounds having the formula: ##STR1## wherein X, Y, R.sub.1, R.sub.2 and R.sub.3 are as defined in the specification. The compounds are useful in the treatment of estrogen dependent illnesses. Methods for synthesizing these compounds are also disclosed.
    Type: Grant
    Filed: July 18, 1997
    Date of Patent: March 9, 1999
    Assignee: Duquesne University of the Holy Ghost
    Inventors: Pui-Kai Li, Kyle W. Selcer
  • Patent number: 5792759
    Abstract: Novel 17-hydroxyiminoalkyl and 17-hydroxyiminomethylalkenyl steroids of the general formula (I) ##STR1## where A, R.sup.1 and R.sup.2 are defined in the specification are disclosed. The compounds have cardiovascular activity. Pharmaceutical compositions containing compounds of formula (I) are also disclosed for the treatment of heart failure and hypertension.
    Type: Grant
    Filed: May 17, 1996
    Date of Patent: August 11, 1998
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
    Inventors: Luisa Quadri, Alberto Cerri, Patrizia Ferrari, Maria Pia Zappavigna
  • Patent number: 5723455
    Abstract: Novel antiandrogenic agents are provided. An exemplary group of compounds has the structural formula (I) ##STR1## wherein R.sup.1 through R.sup.10, a and b are as defined herein. Pharmaceutical compositions and methods for using the compounds of formula (I) to treat androgen-related clinical conditions are provided, as are methods and compositions for using the compounds as contraceptive agents.
    Type: Grant
    Filed: March 11, 1997
    Date of Patent: March 3, 1998
    Assignee: SRI International
    Inventors: Masato Tanabe, Wan-Ru Chao, Wesley K. M. Chong, David F. Crowe
  • Patent number: 5650526
    Abstract: The invention is drawn to a process for the preparation of oxoetiocholenic acid of the formula I ##STR1## by reacting a compound of the formula II ##STR2## with a halonitrile in the presence of a base followed by formation of a 3-ketone group. The intermediate formed is reacted with an acid of the formula HX in an anhydrous medium followed by dehydrohalogenation of the resulting compound in the presence of a base. The intermediate produced then undergoes alkaline hydrolysis followed by a conventional acid treatment to obtain the compound of formula I.
    Type: Grant
    Filed: August 28, 1995
    Date of Patent: July 22, 1997
    Assignee: Roussel Uclaf
    Inventors: Patrick Roussel, Michel Vivat
  • Patent number: 5633392
    Abstract: The invention relates to estrene steroids, which bind to neuroepithelial receptors. The steroid is preferably administered in the form of a pharmaceutical composition containing one or more pharmaceutically acceptable carriers.
    Type: Grant
    Filed: May 31, 1995
    Date of Patent: May 27, 1997
    Assignee: Pherin Corporation
    Inventors: David L. Berliner, Nathan W. Adams, Clive L. Jennings-White
  • Patent number: 5618806
    Abstract: Invented are 17.alpha. and 17.beta.-substituted acyl-3-carboxy aromatic A ring analogues of steroidal synthetic compounds. Representative of such compounds include the following ##STR1## wherein Z is .alpha. or .beta. ##STR2## in which A is absent or present as a linear or branched, saturated or unsaturated hydrocarbon chain containing from 1-6 carbon atoms and R isa) a linear or branched, saturated or unsaturated hydrocarbon chain containing 1-12 carbon atoms substituted with one or more substituents selected from the group consisting of: --OC.sub.6 -C.sub.12 aryl, --OC.sub.1 -C.sub.4 alkyl, halogen, carboxy and --S(O).sub.n .sup.R.sup.7, where n is 0-2 and R.sup.7 is hydrogen or C.sub.1-4 alkyl;b) C.sub.3 -C.sub.8 nonaromatic, unsaturated or saturated, cycloalkyl, optionally substituted with one or more substituents selected from the group consisting of:--OC.sub.6 -C.sub.12 aryl, --(CH.sub.2).sub.m OH, --OC.sub.1 -C.sub.4 alkyl, C.sub.6 -C.sub.12 aryl, C.sub.1 -C.sub.
    Type: Grant
    Filed: October 28, 1994
    Date of Patent: April 8, 1997
    Assignee: SmithKline Beecham Corporation
    Inventors: Dennis A. Holt, Mark A. Levy
  • Patent number: 5561124
    Abstract: The invention relates to substituted 17.alpha.-acyl steroidal 5.alpha.-reductase inhibiting compounds. The invention also relates to pharmaceutical compositions containing these compounds and their use for reducing prostate size and treating prostate adenocarcinoma. Further, the invention describes a process for making these compounds by heating the corresponding substituted 17.beta.-acyl steroid in a solvent, such as ethylene glycol or dimethyl sulfoxide (DMSO), in a base, such as sodium or potassium hydroxide.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: October 1, 1996
    Inventor: Robert L. Webb
  • Patent number: 5523428
    Abstract: A process for the production of 1-methyl-3-keto-.DELTA..sup.1,4 steroids of general formula I ##STR1## in which St symbolizes the radical of asteroid molecule, where a 3-keto-.DELTA..sup.1,4 steroid of general formula II ##STR2## in which St has the above-mentioned meaning, is reacted in an inert solvent in the presence of a nickel salt soluble therein with an organometallic compound of formula III, IV or V ##STR3## where X, Y.sub.1, Y.sub.2, Y.sub.3, Z.sub.1 and Z.sub.2 are as defined in the specification.
    Type: Grant
    Filed: April 18, 1995
    Date of Patent: June 4, 1996
    Assignee: Schering Aktiengesellschaft
    Inventors: Jurgen Westermann, Klaus Nickisch, Annette Prelle
  • Patent number: 5496813
    Abstract: There are described spontaneously dispersible agents containing sterolester and/or sterolphosphor compounds having a pronounced antitumour activity. Novel sterolesters and sterolphosphor compounds, their use for treating tumors, and processes for their preparation are disclosed.
    Type: Grant
    Filed: August 13, 1992
    Date of Patent: March 5, 1996
    Assignee: Marigen S.A.
    Inventors: Carl Eugster, Conrad H. Eugster, Walter Haldemann, Giorgio Rivara
  • Patent number: 5438134
    Abstract: The unsaturated 17.alpha.-cyanomethyl-17.beta.-hydroxy steroids of the formula I, ##STR1## in which R.sub.1 =Me, Eth; R.sub.2 =H, Me; R.sub.3 =H, OH, an acetoxy or alkoxy group; R.sub.4 =H, R.sub.5 =OH, an acetoxy, alkoxy group of R.sub.4 and R.sub.5 together represent a keto- or ketal group and double bonds are contained in the basic structure of the steroid, particularly between the 15 and 16 position in the steroid ring, from unsaturated 17-ketosteroids of the general formula II as described herein with the aforementioned meanings of R.sub.1 to R.sub.5 by reacting the unsaturated 17-ketosteroids with LiCH.sub.2 CN and subsequently hydrolyzing.The compounds of formula I are pharmacologically interesting steroid compounds or also intermediate products for the synthesis of highly-effective steroid products which can be used in human and veterinary medicine for the treatment of endocrine disorders and for reproductive control based on their specific hormonal/anti-hormonal actions.
    Type: Grant
    Filed: June 1, 1993
    Date of Patent: August 1, 1995
    Assignee: Jenapharm GmbH
    Inventors: Gerhard Teichmuller, Gerd Muller
  • Patent number: 5436401
    Abstract: A 22-oxacholecalciferol derivative represented by formula (I): ##STR1## wherein R.sub.1 represents a hydrogen atom or a hydroxyl group; and R.sub.2 and R.sub.3, which may be the same or different, each represent a lower alkyl group having from 1 to 5 carbon atoms,and a process for preparing the same are disclosed. The compound of the present invention has potent differentiation inducing activity and cell proliferation inhibitory activity and is expected to be useful as an anti-tumor agent, an antirheumatic, a treating agent for psoriasis, and a treating agent for hyperparathyreosis. The process of the present invention makes it possible to efficiently produce a desired 22-oxacholecalciferol derivative while reducing by-production.
    Type: Grant
    Filed: June 13, 1994
    Date of Patent: July 25, 1995
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Masahiro Kato, Tetsuhiro Mikami, Kiyoshige Ochi, Hiroyoshi Watanabe, Noboru Kubodera
  • Patent number: 5273971
    Abstract: There are provided 13-alkyl-11beta-phenyl-gonanes of formula I ##STR1## wherein Z is an oxygen atom or N--OH;R.sup.2 is alpha- or beta-position methyl or ethyl;R.sup.1 is selected from heteroaryl radicals, cycloalkyl radicals, cycloalkenyl radicals, aryl radicals, alkenyl radicals, and alkyl radicals where R.sup.2 is in the alpha-position and an ethyl radical where R.sup.2 is in the beta-position; andR.sup.3 and R.sup.4 are selected from one of two different groups of substituent pairs, the group from which the selection is made being determined by the position of R.sup.2.
    Type: Grant
    Filed: July 3, 1989
    Date of Patent: December 28, 1993
    Assignee: Schering Aktiengesellschaft
    Inventors: Stefan Scholz, Eckhard Ottow, Guenter Neef, Walter Elger, Sybille Beier, Krzysztof Chwalisz
  • Patent number: 5272140
    Abstract: The invention relates to 11-aryl steroid derivatives, having the structure ##STR1## wherein: R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are as described in the specificationand to processes for their preparation and to pharmaceuticals comprising these compounds.These compounds exhibit a strong anti-progestinic activity and a weak or non-existent anti-glucocorticoid activity.
    Type: Grant
    Filed: February 27, 1990
    Date of Patent: December 21, 1993
    Assignee: Akzo N.V.
    Inventor: Hubert J. J. Loozen
  • Patent number: 5140106
    Abstract: A process for the production of 3-deoxy-4-ene steroids of the general formula I ##STR1## is described, in which R.sub.1, R.sub.2 and R.sub.3 mean a hydrogen atom or a methyl group,R.sub.4 represents a lower alkyl group, a phenyl group or a free, esterified or etherified hydroxy group,R.sub.5 symbolizes a hydrogen atom, a vinyl group or the grouping --C.tbd.CR.sub.6 with R.sub.6 meaning a hydrogen atom, an alkyl group with a maximum of 4 carbon atoms or a halogen atom,X represents a methylene group, a fluoromethylene group, an ethylidene group or a vinylidene group,Y and U represent a methylene group or an ethylidene group andZ symbolizes a methylene group, an ethylidene group, a vinylidene group, a chloromethylene group or a hydroxymethylene group and in which the bonds represent three single bonds or one double bond and two single bonds or a conjugated double bond.
    Type: Grant
    Filed: January 17, 1991
    Date of Patent: August 18, 1992
    Assignee: Schering Aktiengesellschaft
    Inventors: Ekkehard Winterfeldt, Ulf Tilstamm, Helmut Hofmeister, Henry Laurent
  • Patent number: 5137882
    Abstract: Invented are 3-acetic acid-steroidal compounds, pharmaceutical compositions containing the compounds, and methods of using these compounds to inhibit steroid 5.alpha.-reductase including using these compounds to reduce prostate size and to treat prostatic adenocarcinoma. Also invented are intermediates used in preparing these compounds.
    Type: Grant
    Filed: June 11, 1990
    Date of Patent: August 11, 1992
    Inventors: Dennis A. Holt, Mark A. Levy, Brian W. Metcalf
  • Patent number: 5086047
    Abstract: A compound selected from the group consisting of a compound of the formula ##STR1## wherein R is selected from the group consisting of hydrogen, alkyl, alkylthio and haloalkyl of 1 to 6 carbon atoms, alkenyl and alkynyl of 2 to 6 carbon atoms, optionally substituted arylthio of 6 to 10 carbon atoms, aryl of 6 to 12 carbon atoms, acyl of an organic carboxylic acid of 1 to 12 carbon atoms, --CN, cycloalkyl of 3 to 6 carbon atoms and --(CH.sub.2).sub.m --Re, m is an integer from 1 to 3, Re is --OH or --SH or --Salk, Alk is alkyl of 1 to 6 carbon atoms, X is selected from the group consisting of oxygen, N--O--R.sub.1, ##STR2## or =X is H.sub.2 or ##STR3## R.sub.A and R.sub.B are individually selected from the group consisting of hydrogen, halogen and alkyl of 1 to 6 carbon atoms, R.sub.1 is hydrogen or alkyl of 1 to 6 carbon, R' is hydrogen or acyl, the wavy lines indicate --or -position, Y is selected from the group consisting of oxygen, NOR, ##STR4## or =Y is ##STR5## H.sub.
    Type: Grant
    Filed: December 24, 1990
    Date of Patent: February 4, 1992
    Assignee: Roussel Uclaf, Department des Brevets
    Inventors: Jean-Francois Gourvest, Dominique Lesuisse